Breaking News, Financial News

Financial Report: Merck 2Q

Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 2Q 2Q Revenues: $11.3 billion (+92%) 2Q Earnings: $780.2 million (-51%) YTD Revenues: $22.8 billion (earnings were $11.3 billion YTD09) YTD Earnings: $1.1 billion (-64%) Comments: Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Zetia sales were $564 million (+1%) and Vytorin sales were $490 million (-8%). Isentress sales jumped 55% to $267 million. Cozaar/Hyzaar sales were down 46% to $485 million due to generic competition....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters